Summary:
Click image to enlargeThis study will evaluate intravitreal injections of investigational drug in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) compared with sham control. After completing the study's last visit (Week 76), eligible participants will have the option to enroll in an open-label extension study and receive open-label investigational drug injections.
Qualified Participants Must:
• Be 60 years of age or older at time of consent
• Have geographic atrophy secondary to age-related macular degeneration
• Have visual acuity of 20/320 or better in the study eye
• Not have active cancer in the past 12 months
• Not have any other eye condition other than dry AMD causing vision loss
Qualified Participants May Receive:
1). Reimbursement for their time
2). Transportation assistance
3). Study related care and investigational drug at no cost